Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (October 2026)
26 slides from Clearpoint Neuro's investor presentation, Oct 28, 2026
Slide 1: When Your Path Is Unclear, We Point the Way
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT October 2026 1 © 2026 CLEARPOINT NEURO
Slide 2: Disclaimer: Forward-Looking Statements
DISCLAIMER FORWARD-LOOKING STATEMENTS Statements in this presentation and discussion concerning ClearPoint Neuro’s (the “Company’s”) plans, growth, and strategies may include forward-looking statements within the meaning of the federal securities laws. Statements regarding the Company’s future event
Slide 3: Our Company: Precise Navigation to the Brain and Spine
Neuro Navigation and Robotics* Ablation Therapy and Access Neurocritical Care Management Biologics and Drug Delivery *Robotic product is in development phase. Commercialization is subject to successful development, testing, and applicable regulatory clearance. Most cell and gene therapies referenced
Slide 4: The Future of Neuro Biologics and Drug Delivery Is Here Today
The Future of Neuro Biologics and Drug Delivery is Here Today Our Company Stroke Rehabilitation (7.0m) More than 30 Million people in the U.S. alone are estimated to suffer from severe and debilitating neurological disorders. Neurological diseases cost Americans nearly $800 Billion annually. To redu
Slide 5: Pharma Partners Accepted for FDA Expedited Review
The Future of Neuro Biologics and Drug Delivery is Here Today Our Company Of those 30 million patients, 2.1 million in the U.S. alone have disorders where a ClearPoint BioPharma Partner has already been accepted for FDA expedited review. Importantly, this gene therapy is labeled as a combination pro
Slide 6: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our 4-Phase Strategy Positions ClearPoint for Decades of Growth Our Company 1 With more than $100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expan
Slide 7: The Unique ClearPoint Ecosystem Has Been Years in the Making
The Unique ClearPoint Ecosystem Has Been Years in the Making Design. Discovery. ClearPoint Neuro embraced the unmet need in neuro biologics and drug delivery, and has invested more than $200m over the past 15 years to build a substantial headstart and leadership position. This expansive platform has
Slide 8: Our Installed Base Has Grown to More than 175 Active Global Centers
Active ClearPoint Installation (Additional Sites in Asia, EMEA, LATAM) Our Installed Base Has Grown to More than 175 Active Global Centers Funded. Foundation. © 2026 CLEARPOINT NEURO Over 160 employees worldwide, focused exclusively on Neuro
Slide 9: ~50% of Top Ranked Neurosurgery Programs Use ClearPoint Technology
~50% of the Top Ranked Neurosurgery Programs use ClearPoint Technology Funded. Foundation. https://health.usnews.com/best-hospitals/rankings/neurology-and-neurosurgery - Posted July 29, 2025 Methodology components and weights summarized from publicly described Best Hospitals specialty ranking method
Slide 10: Stress-Tested QMS and Operations
Stress-Tested QMS and Operations Funded. Foundation. We have invested in our Research & Development, Quality, and Manufacturing infrastructure to build confidence for both hospitals and biopharma partners We bring medical device expertise and regulatory combination product acumen to pharmaceutical c
Slide 11: Growth Continues While We Prepare for Commercial Drug Approvals
Growth Continues Today While We Prepare for Commercial Drug Approvals Funded. Foundation. For the year ended December 31, 2025 Unaudited, for the trailing twelve months ended September 30, 2026 Including owned and licensed patents Unaudited, as of, and for the quarter ended September 30, 2026 Solana
Slide 12: Experienced Leadership in Place
Experienced Leadership in Place Funded. Foundation. Megan Faulkenberry Senior Vice President of Quality Mary McNamara-Cullinane Senior Vice President of Regulatory Affairs Paul Larson, MD Chief Medical Officer Joe Burnett President & Chief Executive Officer Jeremy Stigall Chief Business Officer Dani
Slide 13: Our 4-Pillar Growth Strategy
Our 4-Pillar Growth Strategy Fast. Forward. Collective $1.0B Existing Market Opportunity Today *Not all products cleared or approved in all territories. Increasing Global Scale with Clearances in 34 Countries Worldwide* Pre-Commercial Biologics & Drug Delivery Neurosurgery Navigation & Robotics Lase
Slide 14: Pillar 1: Pre-Commercial Biologics & Drug Delivery
Pillar 1: Pre-Commercial Biologics & Drug Delivery Fast. Forward. Leverage Both Commercial and In-Development Delivery and Navigation Tools SmartFlow Software & Biophysical Modeling in Collaboration with NE Scientific $300m+ Existing Market ClearPoint Neuro currently offers a boutique, neuro-focused
Slide 15: Pillar 2: Neuro Navigation & Robotics
Pillar 2: Neuro Navigation & Robotics Fast. Forward. ClearPoint will provide unmatched flexibility by having a single pre-planning software offering several workflows deployed via either MRI, iCT and eventually, Robotics. This strategy balances the consistency of delivery that biopharma partners des
Slide 16: Pillar 3: Laser Therapy & Access
Pillar 3: Laser Therapy & Access Fast. Forward. $75m+ Existing Market VelocityALPHA MRI Conditional Power Drill With Optional ClearPoint Navigation Synergies A Versatile Power Solution for SmartFrame in the MRI and OR ClearPoint Prism is a mobile laser therapy system featuring innovative non‑cooled
Slide 17: Pillar 4: Neurocritical Management
Pillar 4: Neurocritical Management Fast. Forward. ClearPoint’s recent acquisition of IRRAS expands the portfolio with a unique and disruptive solution for neurocritical care and intracranial fluid management. IRRAflow enables active irrigation and controlled drainage of hemorrhage, toxins, and clots
Slide 18: Continued Investment in ClearPoint's 4-Pillar Product Pipeline
Clear and Continued Investment in ClearPoint’s 4-Pillar Product Pipeline Fast. Forward. 2026 2027 2028+ 1 Bioanalytic Lab Active Pathology Lab Active Hot Cell F-18 Radiochemistry Translational Models for tumor, stroke and spinal cord injury 2 CE Mark for 3.x Software Publication of iCT Real-World Da
Slide 19: 2027+ Priorities Across the Four Pillars
2027+ LASER ABLATION THERAPY & ACCESS Add Ablation Coverage & AI Predictive Thermal Modeling Software Launch Velocity MRI Power Drill for Faster Procedure Times NEUROCRITICAL CARE & ACTIVE CSF EXCHANGE Expand Existing Portfolio Into Multiple New Indications Launch Shoreline Software, Cranial Bolt, I
Slide 20: What Does It Mean to Be Essential to the Future of Cell and Gene Therapy?
What Does it Mean to be Essential to the Future of Cell and Gene Therapy? Essential. Everywhere. It starts by being unique. Our Essential. Everywhere. Strategy is to build a new market from the ground up where our unique ecosystem plays an essential role and enables 20,000 annual Cell & Gene Therapy
Slide 21: Our Unique Ecosystem Will Play an Essential Role in Cell and Gene Therapy
Our Unique Ecosystem Will Play An Essential Role in Cell and Gene Therapy Essential. Everywhere. Comprehensive Pre-Planning Navigation Software Modules Flexible Options for Surgeon Selected Navigation Including Frames, Robotics Multiple Biologic Specific & Co-Labeled Routes-of-Administration, includ
Slide 22: 60+ Active Pharma Partners, 25+ Active Clinical Trials
Indication Parkinson’s Disease Epilepsy Huntington’s Rare Genetic Dementias Gliomas Neuromuscular Stroke …and more than 15 additional programs that are undisclosed and in preclinical development. © 2026 CLEARPOINT NEURO ClearPoint Neuro Has 60+ Active Pharma Partners, 25+ Active Clinical Trials Esse
Slide 23: 10+ Programs Are Already Under FDA Expedited Review
Parkinson's (Kenai) – RNDP-001 Parkinson's (Aspen) – ANPD001 Frontotemporal Dementia (AviadoBio) – AVB-101 Friedreich's Ataxia – (Undisclosed) Huntington's (uniQure) – AMT-130 AADC Deficiency (PTC) – KEBILIDI / Upstaza Parkinson's (AskBio) – AB-1005 Parkinson's (BlueRock) – BRT-DA01 Hunter Syndrome
Slide 24: Building Surgical Experience and Capacity to Prepare for Drug Commercialization
Building Surgical Experience and Capacity to Prepare for Drug Commercialization Essential. Everywhere. © 2026 CLEARPOINT NEURO Existing CLPT Navigation Site Experienced CLPT Navigation Site and Participant in Active CGT Trial
Slide 25: Commercial Drug Delivery and 2027+ Plans
5 COMMERCIAL DRUG DELIVERY Add Capacity for 5,000 cell & gene therapy procedures Launch Co-Labeled Products with 10+ partners that are already under FDA Expedited Review across 8 Indications 3 2 2027+ LASER ABLATION THERAPY & ACCESS Add Ablation Coverage & AI Predictive Thermal Modeling Software Lau
Slide 26: Our 4-Phase Strategy Positions ClearPoint for Decades of Growth
Our 4-Phase Strategy Positions ClearPoint for Decades of Growth Our Company 1 With more than $100m of capital invested over the past 5 years, our large commercial footprint, rapidly expanding installed base, high-capacity manufacturing, stress-tested quality system, global regulatory reach and expan
ClearPoint Neuro — Investor Presentation (October 2026) on 6ix